ATE227136T1 - Mittel zur verstaerkten aufnahme polarer arzneistoffe aus dem kolon - Google Patents

Mittel zur verstaerkten aufnahme polarer arzneistoffe aus dem kolon

Info

Publication number
ATE227136T1
ATE227136T1 AT96927128T AT96927128T ATE227136T1 AT E227136 T1 ATE227136 T1 AT E227136T1 AT 96927128 T AT96927128 T AT 96927128T AT 96927128 T AT96927128 T AT 96927128T AT E227136 T1 ATE227136 T1 AT E227136T1
Authority
AT
Austria
Prior art keywords
colon
polar
agents
medicinal substances
enhanced absorption
Prior art date
Application number
AT96927128T
Other languages
English (en)
Inventor
Peter James Watts
Lisbeth Illum
Original Assignee
West Pharm Serv Drug Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Pharm Serv Drug Res Ltd filed Critical West Pharm Serv Drug Res Ltd
Application granted granted Critical
Publication of ATE227136T1 publication Critical patent/ATE227136T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96927128T 1995-08-08 1996-08-08 Mittel zur verstaerkten aufnahme polarer arzneistoffe aus dem kolon ATE227136T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9516268.1A GB9516268D0 (en) 1995-08-08 1995-08-08 Compositiion for enhanced uptake of polar drugs from the colon
PCT/GB1996/001933 WO1997005903A2 (en) 1995-08-08 1996-08-08 Composition for enhanced uptake of polar drugs from the colon

Publications (1)

Publication Number Publication Date
ATE227136T1 true ATE227136T1 (de) 2002-11-15

Family

ID=10778960

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96927128T ATE227136T1 (de) 1995-08-08 1996-08-08 Mittel zur verstaerkten aufnahme polarer arzneistoffe aus dem kolon

Country Status (13)

Country Link
US (1) US6200602B1 (de)
EP (1) EP0843558B1 (de)
JP (1) JPH11510506A (de)
AT (1) ATE227136T1 (de)
AU (1) AU707587B2 (de)
CA (1) CA2227764A1 (de)
DE (1) DE69624711T2 (de)
DK (1) DK0843558T3 (de)
ES (1) ES2186798T3 (de)
GB (1) GB9516268D0 (de)
NO (1) NO980047L (de)
PT (1) PT843558E (de)
WO (1) WO1997005903A2 (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885567A (en) * 1993-10-22 1999-03-23 University Of Connecticut Treatment of infection in fowl by oral administration of avian interferon proteins
GB9700624D0 (en) 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
JP2002510319A (ja) 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6423334B1 (en) 1997-10-01 2002-07-23 Elan Corporation, Plc Composition and method for enhancing transport across gastrointestinal tract cell layers
SE9703691D0 (sv) * 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions
FR2775188B1 (fr) 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
EP1080103A4 (de) * 1998-05-21 2003-07-02 Isis Pharmaceuticals Inc Zubereitungen und verfahren zur nicht-parenteralen verabreichung von oligonukleotiden
GB9824604D0 (en) * 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
JP2002531518A (ja) * 1998-12-04 2002-09-24 プロヴァリス・ユーケー・リミテッド インスリン含有医薬組成物
ES2301477T3 (es) * 1999-02-22 2008-07-01 Merrion Research I Limited Forma de dosificacion oral solida que contiene un potenciador.
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
EP1239835B1 (de) 1999-12-23 2013-03-20 Bend Research, Inc. Arzneizusammensetzung mit erhöhter arzneistoffkonzentration
KR20010082721A (ko) * 2000-02-18 2001-08-30 고니시 진우에몬 지방산 함유 조성물
JP2001240558A (ja) * 2000-02-29 2001-09-04 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
CA2438707A1 (en) * 2001-02-16 2002-08-22 Akihiro Matsuura Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
EP1900364B1 (de) * 2001-04-18 2013-09-25 ProMetic BioSciences Inc. Fettsäuren mit mittlerer Kettenlänge, Glyceride und Analoge als neutrophile Haltbarkeits- und Aktivierungsfaktoren
EP1392272B1 (de) 2001-05-11 2014-08-06 Merrion Research III Limited Permeationsverbesserer
WO2002092070A1 (en) * 2001-05-11 2002-11-21 Elan Corporation, Plc Isostearic acid salts as permeation enhancers
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
AU2002330692A1 (en) 2001-07-02 2003-01-21 Elan Corporation, Plc. Delivery of a bioactive material
GB2392674B (en) * 2001-07-06 2005-08-10 Geron Corp Mesenchymal cells and osteoblasts from human embryonic stem cell
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
ES2388968T3 (es) * 2001-11-02 2012-10-22 Giuliani International Limited Inhibidores de Smad7 para el tratamiento de enfermedades del SNC
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
WO2004052405A1 (en) * 2002-12-11 2004-06-24 Chong Kun Dang Pharmaceutical Corp. Oral formulations for poorly absorptive hydrophilic drugs
CN100427081C (zh) 2003-02-07 2008-10-22 普罗米蒂克生物科学公司 作为红细胞生成刺激剂的中链长脂肪酸类、甘油酯类和类似物
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
KR101152470B1 (ko) 2003-08-13 2012-06-01 바이오콘 리미티드 치료제용 마이크로-입자 지방산 염 고형 투약 제형
US20050163849A1 (en) * 2003-10-31 2005-07-28 Wong Patrick S. Compositions and dosage forms for enhanced absorption of iron
ES2425937T3 (es) * 2004-03-24 2013-10-18 Takeda Pharmaceutical Company Limited Estabilizante de emulsión
KR20070044805A (ko) * 2004-04-15 2007-04-30 키아스마, 인코포레이티드 생물학적 장벽 투과를 촉진시킬 수 있는 조성물
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
PT1773878E (pt) * 2004-07-19 2015-06-05 Biocon Ltd Conjugados de insulina-oligómero, formulaçôes e usos dos mesmos
US20080214618A1 (en) * 2004-08-23 2008-09-04 Auckland Uniservices Limited Gastric Therapies Amd Compositions Therefor
MY139644A (en) * 2005-02-17 2009-10-30 Palm Nutraceuticals Sdn Bhd Improving the quality of crude oils and fats and recovery of minor components
CA2623678A1 (en) * 2005-09-29 2007-04-05 Repros Therapeutics Inc. Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
JP5047978B2 (ja) * 2005-10-13 2012-10-10 バイオコン・リミテッド インスリン複合体の調製のための方法
US8920918B2 (en) * 2005-10-31 2014-12-30 Kee Action Sports Technology Holdings, Llc Oil and polyethylene glycol fill material for use in paintball shells
WO2008020318A2 (en) * 2006-03-30 2008-02-21 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
CA2648594C (en) * 2006-04-07 2012-10-16 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
WO2007146234A2 (en) * 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
NZ585135A (en) * 2007-10-16 2012-08-31 Biocon Ltd An orally administerable solid pharmaceutical composition comprising in-105 and a process thereof
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
JP2011519928A (ja) * 2008-05-07 2011-07-14 メリオン・リサーチ・Ｉｉｉ・リミテッド ペプチドの組成物及びその調製方法
GB0808537D0 (en) * 2008-05-12 2008-06-18 Archimedes Dev Ltd Compositions
AU2015201581B2 (en) * 2008-09-17 2017-03-09 Amryt Endo, Inc. Pharmaceutical Compositions and Related Methods of Delivery
ES2629131T3 (es) 2008-09-17 2017-08-07 Chiasma Inc. Composiciones farmacéuticas y métodos de suministro relacionados.
US20100064927A1 (en) * 2008-09-17 2010-03-18 Aldo Perrone Starch-based paintball fill material
AR075613A1 (es) * 2009-02-25 2011-04-20 Merrion Res Iii Ltd Composicion y suministro de drogas de bifosfonato. metodo de tratamiento
ES2929471T3 (es) 2009-06-18 2022-11-29 Acerus Pharmaceuticals Usa Llc Administración segura de desmopresina
CN102803842B (zh) 2009-06-25 2015-07-01 皇家飞利浦电子股份有限公司 热管理设备
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CA2769633C (en) 2009-07-31 2017-06-06 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
AU2010339907A1 (en) 2009-12-16 2012-07-05 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
WO2011086093A2 (en) * 2010-01-12 2011-07-21 Novo Nordisk A/S Pharmaceutical compositions for oral administration of insulin peptides
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
JP2014501784A (ja) 2011-01-07 2014-01-23 メリオン・リサーチ・Ｉｉｉ・リミテッド 経口投与用の鉄の医薬組成物
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
RS66942B1 (sr) 2015-02-03 2025-07-31 Amryt Endo Inc Lečenje akromegalije oralnim oktreotidom
GB201511284D0 (en) * 2015-06-26 2015-08-12 Univ Witwatersrand Jhb An oral pharmaceutical dosage form for the delivery of a peptide and/or protein
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
GB201904771D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
NZ228285A (en) 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
EP0351651B1 (de) 1988-07-21 1993-09-15 F. Hoffmann-La Roche Ag Insulinzubereitung
ZA906186B (en) 1989-09-11 1991-06-26 Hoffmann La Roche Pharmaceutical preparations
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
BE1003677A3 (nl) 1990-01-29 1992-05-19 Schacht Etienne Werkwijze voor het bereiden van azobevattende polymeren en het gebruik ervan als geneesmiddelafgiftesystemen.
BR9106419A (pt) 1990-05-04 1993-05-04 Perio Prod Ltd Sistema de liberacao colonica de medicamentos
IT1255895B (it) 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
AU692506B2 (en) * 1993-11-17 1998-06-11 Ibah, Inc. Transparent liquid for encapsulated drug delivery
JPH08208510A (ja) 1994-11-03 1996-08-13 F Hoffmann La Roche Ag インターフェロン組成物

Also Published As

Publication number Publication date
JPH11510506A (ja) 1999-09-14
NO980047D0 (no) 1998-01-06
DK0843558T3 (da) 2003-03-03
DE69624711D1 (de) 2002-12-12
US6200602B1 (en) 2001-03-13
WO1997005903A2 (en) 1997-02-20
ES2186798T3 (es) 2003-05-16
DE69624711T2 (de) 2003-07-24
EP0843558B1 (de) 2002-11-06
WO1997005903A3 (en) 1997-03-13
GB9516268D0 (en) 1995-10-11
CA2227764A1 (en) 1997-02-20
PT843558E (pt) 2003-03-31
AU707587B2 (en) 1999-07-15
NO980047L (no) 1998-01-06
EP0843558A2 (de) 1998-05-27
AU6705996A (en) 1997-03-05

Similar Documents

Publication Publication Date Title
ATE227136T1 (de) Mittel zur verstaerkten aufnahme polarer arzneistoffe aus dem kolon
UA42061C2 (uk) Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса
AU677219B2 (en) Device for oral delivery of substances
PT825858E (pt) Capsulas de libertacao dependente do tempo contendo acidos poliinsaturados omega-3 para o tratamento da doenca inflamatoria do intestino
ATE248589T1 (de) Matrix zur gesteuerten freisetzung von arzneistoffen
ES2149979T3 (es) Composicion estabilizada para la administracion oral de peptidos.
MY102459A (en) Oral sustained release pharmaceutical preparation.
KR890009376A (ko) 분무 건조된 이부프로펜
DE69532031D1 (de) Schilddrüsenhormone enthaltende mittel
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
EP1365749A4 (de) Prozess zur herstellung von pharmazeutischen zusammensetzungen zur verwendung mit weichgelatine formulierungen
CA2180571A1 (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
EP0804172A4 (de)
NZ337418A (en) Paracetamol composition with improved rate of absorption
PL327323A1 (en) Orally administered 5-asa containing pharmaceutic composition of modified active substance release and method of treating intestinal diseases
DK0615441T3 (da) Ibuprofenholdigt lægemiddel til akut brug og dets anvendelse
AU1879597A (en) Tetraether lipids and liposomes containing said lipids, and use of the same
KR970703774A (ko) 활성물질 방출이 지연된 카바마제핀 약제(Carbamazepine medicament with retarded active substance release)
CO4970832A1 (es) Nuevas formulaciones y procesos para su fabricacion
DE69634080D1 (de) Mittel zur verhinderung der truebung der vorderen linsenkapsel
GB2318056A (en) Composition for enhanced uptake of polar drugs from the colon
MY135473A (en) Cigarette filter
DE69911224D1 (de) Geschmacksmaskierte kautablette mit sofortiger wirkstofffreisetzung sowie herstellungsverfahren
KR970700505A (ko) 산 활성물질을 갖는 경구투여 형태 및 그의 제조방법(oral dosage form containing colestipol as a carrier and acidic active substances and a process for producing the same)
ATE210428T1 (de) Geschmacksmaskierte wässrige lösungen enthaltend ibuprofen und menthol

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0843558

Country of ref document: EP

REN Ceased due to non-payment of the annual fee